Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs


Authors: Q. Li, C. Chan, N. Peterson, R.N. Hanna, A. Alfaro, K.L. Allen, H. Wu, W.F. Dall'Acqua, M.J. Borrok and J.L. Santos

Journal: ACS Chemical Biology

DOI: 10.1021/acschembio.0c00003

Publication - Abstract

March 10, 2020

mRNA Nucleic Acid Lipid Nanoparticles Targeted Drug Delivery

Abstract

Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted delivery to tissues of interest. Systemic administration of lipid nanoparticle (LNP)-encapsulated mRNA leads to a protein expressed predominantly in the liver and spleen. Here, LNP encapsulating mRNA was covalently conjugated to an antibody, specifically binding plasmalemma vesicle-associated protein (PV1) as a means to target lung tissue. Systemic administration of PV1-targeted LNPs demonstrated significantly increased delivery of mRNA to the lungs and a 40-fold improvement in protein expression in the lungs, compared with control LNPs. We also investigated the effect of LNP size to determine optimal tissue distribution and transfection. Larger-size PV1-targeted LNPs not only have the elasticity to target the PV1 expressed in the caveolae but also enable robust mRNA expression in the lungs. Targeted delivery of mRNA to the lungs is a promising approach in the treatment of lung diseases.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

May 04, 2016
Journal of Drug Targeting

Advances in RNAi Therapeutic Delivery to Leukocytes using Lipid Nanoparticles

S. Ramishetti, D. Landesman-Milo and D. Peer

Hematology siRNA Oncology

Small interfering RNAs (siRNAs) therapeutics has advanced into clinical trials for liver diseases and solid tumors, but remain a challenge for manipulating leukocytes fate due to lack of specificity and safety issues. Leukocytes ingest pathogens an...

Read More


Publication - Abstract

Apr 30, 2019
Cellular and Molecular Life Sciences

KIF2A Characterization After Spinal Cord Injury

O. Seira, J. Liu, P. Assinck, M. Ramer, and W. Tetzlaff

Neuroscience Nucleic Acid Lipid Nanoparticles siRNA
Axons in the central nervous system (CNS) typically fail to regenerate after injury. This failure is multi-factorial and caused in part by disruption of the axonal cytoskeleton. The cytoskeleton, in particular microtubules (MT), plays a critical role in axonal transport and axon ...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up